Beraprost

• CAT Number: I023286
• CAS Number: 88430-50-6
• Molecular Formula: C24H30O5
• Molecular Weight: 398.49
• Purity: ≥95%
• Synonyms: Beraprost; MDL 201229; MDL-201229; ML 1229; ML-1229
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
• IUPAC Name: 1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-
• InChI: InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+
• InChIKey: CTPOHARTNNSRSR-OUKQBFOZSA-N
• SMILES: O=C(O)CCCC1=C(OC2C3C(/C=C/C(O)C(C)CC#CC)C(O)C2)C3=CC=C1

Beraprost (Cat.No:I023286) is a synthetic prostacyclin analog that has vasodilatory and antiplatelet effects. It is used to treat peripheral artery disease and pulmonary arterial hypertension. Beraprost works by relaxing blood vessels and preventing blood clots from forming. It is available in oral and injectable forms. Beraprost has shown to be effective in improving symptoms and increasing exercise capacity in patients with these conditions.

Reference

1: Zhang P, Xu L, Guan H, Liu L, Liu J, Huang Z, Cao X, Liao Z, Xiao H, Li Y. Beraprost sodium, a prostacyclin analogue, reduces fructose-induced hepatocellular steatosis in mice and in vitro via the microRNA-200a and SIRT1 signaling pathway. Metabolism. 2017 Aug;73:9-21. doi: 10.1016/j.metabol.2017.05.003. Epub 2017 May 11. PubMed PMID: 28732575.
2: Zhang H, Li X, Huang J, Li H, Su Z, Wang J. Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis. Medicine (Baltimore). 2016 Jan;95(4):e2575. doi: 10.1097/MD.0000000000002575. Review. PubMed PMID: 26825901; PubMed Central PMCID: PMC5291571.
3: Del Pozo R, Hernandez Gonzalez I, Escribano-Subias P. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med. 2017 Jun;11(6):491-503. doi: 10.1080/17476348.2017.1317599. Epub 2017 Apr 24. Review. PubMed PMID: 28399721.
4: Kim M, Kim JU, Kim SM, Kim H. Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis. Int Urol Nephrol. 2017 Jul;49(7):1287-1295. doi: 10.1007/s11255-017-1586-y. Epub 2017 Apr 13. PubMed PMID: 28409403.
5: Shimamura M, Miyakawa J, Doi M, Okada K, Kurumatani H, Mori Y, Oshida K, Nakajo I, Oikawa K, Ushigome F, Miyashita A, Isono M, Miyamoto Y. The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. J Clin Pharmacol. 2017 Apr;57(4):524-535. doi: 10.1002/jcph.835. Epub 2016 Nov 15. PubMed PMID: 27681484.
6: El Yafawi R, Wirth JA. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management? Curr Hypertens Rep. 2017 Oct 25;19(12):97. doi: 10.1007/s11906-017-0796-0. Review. PubMed PMID: 29071454.
7: Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S, Okazaki S, Matsuura H, Fujii S, Matsuda F, Goto Y, Mochizuki H, Kurumatani H, Miyamoto M. Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. Eur J Pharmacol. 2013 Aug 15;714(1-3):325-31. doi: 10.1016/j.ejphar.2013.07.032. Epub 2013 Jul 30. PubMed PMID: 23911885.
8: Perez Diaz N, Zloh M, Patel P, Mackenzie LS. In silico modelling of prostacyclin and other lipid mediators to nuclear receptors reveal novel thyroid hormone receptor antagonist properties. Prostaglandins Other Lipid Mediat. 2016 Jan;122:18-27. doi: 10.1016/j.prostaglandins.2015.12.002. Epub 2015 Dec 11. PubMed PMID: 26686607.
9: Oshida K, Shimamura M, Seya K, Ando A, Miyamoto Y. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):117-128. doi: 10.1007/s13318-016-0327-4. PubMed PMID: 26961540.
10: Velayati A, Valerio MG, Shen M, Tariq S, Lanier GM, Aronow WS. Update on pulmonary arterial hypertension pharmacotherapy. Postgrad Med. 2016 Jun;128(5):460-73. doi: 10.1080/00325481.2016.1188664. Review. PubMed PMID: 27232660.
11: Chen Y, Yang S, Yao W, Zhu H, Xu X, Meng G, Zhang W. Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF β-Smad signal pathway. PLoS One. 2014 May 22;9(5):e98483. doi: 10.1371/journal.pone.0098483. eCollection 2014. PubMed PMID: 24852754; PubMed Central PMCID: PMC4031177.
12: Arai T. Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. Adv Ther. 2013 May;30(5):528-40. doi: 10.1007/s12325-013-0030-7. Epub 2013 Jun 8. PubMed PMID: 23749750.
13: Lee E, Kim J, Kim YM, Ha KS, Jeoung DI, Sin JI, Choe J. Beraprost enhances production of antigen-specific IgG isotypes without modulating germinal center B cell generation and the affinity maturation. Int Immunopharmacol. 2013 Apr;15(4):735-42. doi: 10.1016/j.intimp.2013.03.004. Epub 2013 Mar 15. PubMed PMID: 23499642.
14: Umemiya S, Sakamoto D, Kawauchi G, Hayashi Y. Enantioselective Total Synthesis of Beraprost Using Organocatalyst. Org Lett. 2017 Mar 3;19(5):1112-1115. doi: 10.1021/acs.orglett.7b00134. Epub 2017 Feb 23. PubMed PMID: 28231006.
15: Misawa H, Ohashi W, Tomita K, Hattori K, Shimada Y, Hattori Y. Prostacyclin mimetics afford protection against lipopolysaccharide/d-galactosamine-induced acute liver injury in mice. Toxicol Appl Pharmacol. 2017 Nov 1;334:55-65. doi: 10.1016/j.taap.2017.09.003. Epub 2017 Sep 5. PubMed PMID: 28887131.
16: Sakao S, Tanabe N, Kasahara Y, Tatsumi K. Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium, an oral prostacyclin analogue. Intern Med. 2014;53(17):1913-20. Epub 2014 Sep 1. PubMed PMID: 25175122.
17: Ono S, Nagaoka T, Omae T, Tanano I, Kamiya T, Otani S, Ishibazawa A, Yoshida A. Beraprost sodium, a stable prostacyclin analogue, elicits dilation of isolated porcine retinal arterioles: roles of eNOS and potassium channels. Invest Ophthalmol Vis Sci. 2014 Jul 31;55(9):5752-9. doi: 10.1167/iovs.14-14902. PubMed PMID: 25082887.
18: Takenaka M, Iio A, Sato R, Sakamoto T, Kurumatani H; KT-140 Clinical Study Group. A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease. J Vet Intern Med. 2018 Jan;32(1):236-248. doi: 10.1111/jvim.14839. Epub 2017 Nov 13. PubMed PMID: 29131397; PubMed Central PMCID: PMC5787173.
19: Choe J, Yoon Y, Kim J, Jung YJ. Positive feedback effect of PGE(2) on cyclooxygenase-2 expression is mediated by inhibition of Akt phosphorylation in human follicular dendritic cell-like cells. Mol Immunol. 2017 Jul;87:60-66. doi: 10.1016/j.molimm.2017.04.004. Epub 2017 Apr 11. PubMed PMID: 28407559.
20: Yoon HS, Choi WJ, Sung IH, Lee HS, Chung HJ, Lee JW. Effects of Beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease. Clin Orthop Surg. 2013 Jun;5(2):145-51. doi: 10.4055/cios.2013.5.2.145. Epub 2013 May 15. PubMed PMID: 23730480; PubMed Central PMCID: PMC3664675.